Sanjay Ramakrishnan

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Sanjay Ramakrishnan, Dan V. Nicolau, Beverly Langford et al. · The Lancet Respiratory Medicine · 2021 · 427 citations · Full text

Early Covid-19, Respiratory Diseases, Respiratory Infection +6

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 302 citations · Full text

Epidemiology, Respiratory Diseases, Medicine +6

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

Simon Couillard, Annette Laugerud, Maisha Jabeen et al. · Thorax · 2021 · 160 citations · Full text

Inflammation, Asthma, Anti-inflammatory +13

Survival analysis of patients on maintenance hemodialysis

A Chandrashekar, Sanjay Ramakrishnan, DRangarajan Rangarajan · Indian Journal of Nephrology · 2014 · 98 citations · Full text

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

Sanjay Ramakrishnan, Richard Russell, Hafiz Taha Mahmood et al. · The Lancet Respiratory Medicine · 2024 · 81 citations · Full text

Asthma, Inflammatory Lung Disease, Lung Inflammation +8